Additionally, other PD-L1 inhibitors, including durvalumab and avelumab, have also gained regulatory approvals for bladder cancer treatment based on clinical trial evidence, expanding the available therapeutic options (102, 103). This evidence concerns the gene CD274 and urinary bladder cancer.